← All stocks

Idexx Laboratories Inc

IDXXBiotechnologyLatest filing used: 2026-11-02Filings on SEC EDGAR ↗

Above fair value Strong balance sheet High cash margin

Fair value per share

$184.66

from SEC filings only

Last close

$704.46

Nov 13, 2026

281.5% above fair value

Margin of safety price
$138.50
25% below fair value
Stress case
$96.87
if things go badly

Its filings point to about $184.66 a share, most likely between $141.38 and $224.96.

Where it sits

67 of the 653 stocks we value that have a close are even further above their estimates.

Counts the 653 stocks that have both a value and a close as of Nov 13. Positions are squeezed so the biggest gaps fit.

The short case

In favour

  • It turns about 22% of its sales into cash in a typical year.
  • Sales have grown about 10% a year over the last five years.
  • It earns high returns on the money invested in it.

Against

  • Its last close is about 281% above what its filings say it is worth.

Written automatically from the filings, by the same rules for every company. Not a recommendation.

Price tags

The last close next to our fair value, the filings-based estimate above. Profit and cash flow: the 12 months to September 30, 2026.

MeasureAt last close$704.46Nov 13At our fair value$184.66
Market valueAll 79 million shares at that price (the diluted count, which includes stock options and awards)$55.7B$14.6B
Price / earnings (P/E)Dollars paid for each $1 of yearly profit47.1×12.3×
Price / free cash flowDollars paid for each $1 of cash left each year after paying for equipment42.7×11.2×
EV / EBITDAPrice of the whole business (shares plus debt, less cash) for each $1 of yearly profit before interest, tax and wear and tear33.6×8.9×

Our own arithmetic on the filings, the last close and our fair value, which is an estimate. One unusual year can push any of these very high or very low. How we work these out

Five areas

20 of 25 checks passedStrong in 4 of 5 areas

GrowthStrong · 5 of 5
  • Revenue up 5%+ a year over 3 years (passed)
  • Revenue up 5%+ a year over 5 years (passed)
  • Earnings per share up 5%+ a year over 5 years (passed)
  • Revenue up over the last 12 months (passed)
  • Earnings per share up over the last 12 months (passed)
ProfitabilityStrong · 5 of 5
  • Return on equity of 15%+ (last 12 months) (passed)
  • Return on equity of 12%+ (5-year average) (passed)
  • Return on invested capital of 10%+ (5-year average) (passed)
  • Operating margin of 10%+ (5-year average) (passed)
  • Operating margin holding up (last 12 months vs 5 years) (passed)
Cash generationStrong · 5 of 5
  • Cash earnings positive in almost every year (at most one bad year) (passed)
  • Typical year turns 10%+ of revenue into cash (passed)
  • Latest year at or above the typical year (passed)
  • Free cash flow positive (last 12 months) (passed)
  • Revenue larger than 5 years ago (passed)
Balance sheetStrong · 4 of 5
  • Debt no larger than equity (passed)
  • Cash and short-term investments exceed debt (not passed)
  • Positive shareholders' equity (passed)
  • Debt clearly tagged in the filings (passed)
  • Operating margin above zero (last 12 months) (passed)
Shareholder returnsWeak · 1 of 5
  • Pays a dividend (not passed)
  • Dividend paid in each of the last 5 years (not passed)
  • Dividend grew over 5 years (no data)
  • Pays out 75% or less of earnings (no data)
  • Share count flat or falling over 5 years (passed)

Flags

No flags raised in the latest filing.

How we got this number

In a typical year IDXX kept 22% of its revenue as cash after running and maintaining the business (before interest). We assume revenue grows 8.5% a year for five years, then slows to 2.5% by year ten, and discount the cash at 10.1% a year (the 10-year Treasury yield plus 5 points, blended with the cost of its debt). That is worth $184.66 a share today.

Technical details
Model
Discounted cash flow on cash earnings
Cash-earnings margin: typical year (worst / best 3-year stretch)
21.8% (19.4% / 23.3%)
Years used
2018–2025
Revenue growth, years 1–5 (range tested)
8.5% (4 to 14%)
Capital needed per $1 of new revenue
$0.19 equipment, $0.04 working capital
Discount rate
10.1%
Revenue base
$4.3B (lower of TTM and last FY)
Debt / cash
$0.4B / $0.2B
Value if investors require Treasury + 3 / + 8 points (we use + 5)
$237.06 / $137.06
If growth after year 10 keeps today's returns
$210.62
Likely range
10th–90th percentile of 4,000 runs with different assumptions
Required return
10-year Treasury 5.15% (2026-11-13) + 5%

What the price assumes

For our model to reach the last close of $704.46 (Nov 13, 2026), IDXX would have to keep 80¢ of every $1 of sales as cash. Its best year was 26¢ and a typical year 22¢.

What the price needs
80¢
Its typical year
22¢
Its last 3 years
23¢
Its best year
26¢

So the price is betting on more than we assume: a higher margin than in any of the 8 years we checked, faster or longer growth than our rules allow, a discount rate below our 10.1%, or something our model leaves out. Our growth rules are cautious: growth is capped at 15% a year and adds no value after year 10.

Typical, best and worst years are from the 8 years we checked in its filings (2018–2025). Everything else stays as described above, including the growth path and the discount rate.

Technical details

Value per share is a straight line in the margin until it reaches zero: value = margin × cash factor − (growth spending + debt and other claims) per share. We solve for the margin that gives the last close, with growth, discount rate, equipment and working capital held as in the main model.

Revenue base $4.3B. Growth 8.5% for five years, fading to 2.5% by year 10. Discount rate 10.1%. At 21.8¢ the filings-based value is $184.66. Each extra 1¢ of margin adds $8.92 a share. The last close is $704.46, which is $519.80 above the filings-based value, so the margin would have to rise by 58.3¢, to 80.1¢.

Terminal rule: Growth after year 10 earns only the discount rate, so it adds no value.

Ten years of results

Revenue

$4.3B in FY2025, up 10% on the year before

FY2016: $1.8BFY2017: $2.0BFY2018: $2.2BFY2019: $2.4BFY2020: $2.7BFY2021: $3.2BFY2022: $3.4BFY2023: $3.7BFY2024: $3.9BFY2025: $4.3B$2.5B$5BFY16FY19FY22FY25$4.3B
Show as table
YearRevenue
FY2016$1.8B
FY2017$2.0B
FY2018$2.2B
FY2019$2.4B
FY2020$2.7B
FY2021$3.2B
FY2022$3.4B
FY2023$3.7B
FY2024$3.9B
FY2025$4.3B

Cash earnings as a share of sales

25.5% of sales in FY2025

FY2018: 16.8%FY2019: 17.7%FY2020: 23.6%FY2021: 22.4%FY2022: 17.3%FY2023: 23.2%FY2024: 21.2%FY2025: 25.5%0%15%30%FY16FY19FY22FY2526%
Show as table
YearCash earnings as a share of sales
FY2016–
FY2017–
FY201816.8%
FY201917.7%
FY202023.6%
FY202122.4%
FY202217.3%
FY202323.2%
FY202421.2%
FY202525.5%

Shares outstanding

Share count fell 11% over 9 years

FY2016: 91MFY2017: 90MFY2018: 88MFY2019: 88MFY2020: 87MFY2021: 87MFY2022: 85MFY2023: 84MFY2024: 83MFY2025: 81M050M100MFY16FY19FY22FY2581M
Show as table
YearShares outstanding
FY201691M
FY201790M
FY201888M
FY201988M
FY202087M
FY202187M
FY202285M
FY202384M
FY202483M
FY202581M

No dividends paid in these years.

Delayed quote

Delayed price and chart from TradingView. This site does not receive or store these prices, and the fair value above does not use them. Showing the chart sends TradingView this page's address, the widget type, the ticker and your IP address, and TradingView may collect analytics; see Privacy.

Open on Yahoo Finance ↗

Sources. Company figures: SEC EDGAR (XBRL filings), latest filing used 2026-11-02. Interest rate: U.S. Treasury, 10-year par yield, 2026-11-13. Last close: IEX Historical Data, 2026-11-13. Price tags: our own arithmetic on the SEC figures, the last close and our fair value.